SynthesisDiabetes, obesity & metabolism2026
Low immunogenicity of insulin efsitora alfa in participants with type 1 and type 2 diabetes mellitus.
Synthesis in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Low immunogenicity of insulin efsitora alfa in participants with type 1 and type 2 diabetes mellitus.Diabetes, obesity & metabolism · 2026Pooled it
- Characterisation of steady-state pharmacokinetics and glucodynamics of once-weekly insulin efsitora alfa in individuals with type 2 diabetes.Diabetes, obesity & metabolism · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
aimsTo evaluate treatment-emergent antidrug antibodies (TE ADA) in once-weekly basal insulin efsitora-treated participants with type 1 and type 2 diabetes mellitus (T1DM and T2DM) from 5 phase 3 clinical trials and their potential impact on pharmacokinetics, efficacy and safety. MATERIALS AND
methodsSerum samples were collected at baseline and throughout the studies. ADA were measured and characterised for their cross-reactivity to native insulin or ability to neutralise efsitora or endogenous insulin. ADA impact on the pharmacokinetics, efficacy and safety of efsitora was evaluated by comparing the clearance of efsitora, glycated haemoglobin (HbA1c) change from baseline at the primary endpoint, and incidence of treatment-emergent hypersensitivity reactions or injection site reactions by ADA status, respectively.
resultsAbout 0.6% and 3.0% of efsitora-treated participants with T1DM (341) and T2DM (1861), respectively, developed TE ADA. Cross-reactive antibodies to native insulin and neutralising antibodies against efsitora and native insulin were observed in 1.7%, 1.1% and 0.8% of efsitora-treated participants with T2DM, respectively, but not in those with T1DM. Maximum ADA titres ranged from 1:40 to 1:81 920, with a median of 1:80. The clearance of efsitora was similar between baseline ADA+ and ADA- groups. TE ADA status did not significantly affect HbA1c reduction or cause hypersensitivity or injection site reactions in efsitora-treated participants.
conclusionsEfsitora caused an immunogenic response in up to 3.0% of participants with T1DM and T2DM. Descriptive analysis indicates that the immunogenicity of efsitora did not noticeably impact its pharmacokinetics, efficacy or safety. The molecular design of efsitora may contribute to its low immunogenicity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.